Linked dual-class HIV resistance mutations are associated with treatment failure.

Abstract

We hypothesized that HIV-1 with dual-class but not single-class drug resistance mutations linked on the same viral genome, present in the virus population before initiation of antiretroviral therapy (ART), would be associated with failure of ART to suppress viremia. To test this hypothesis, we utilized an ultrasensitive single-genome sequencing assay that detects rare HIV-1 variants with linked drug resistance mutations (DRMs). A case (ART failure) control (nonfailure) study was designed to assess whether linkage of DRMs in pre-ART plasma samples was associated with treatment outcome in the nevirapine/tenofovir/emtricitabine arm of the AIDS Clinical Trials Group A5208/Optimal Combined Therapy After Nevirapine Exposure (OCTANE) Trial 1 among women who had received prior single-dose nevirapine. Ultrasensitive single-genome sequencing revealed a significant association between pre-ART HIV variants with DRMs to 2 drug classes linked on the same genome (dual class) and failure of combination ART with 3 drugs to suppress viremia. In contrast, linked, single-class DRMs were not associated with ART failure. We conclude that linked dual-class DRMs present before the initiation of ART are associated with ART failure, whereas linked single-class DRMs are not.

• Authors: Valerie F Boltz, Wei Shao, Michael J Bale, Elias K Halvas, Brian Luke, James A McIntyre, Robert T Schooley, Shahin Lockman, Judith S Currier, Fred Sawe, Evelyn Hogg, Michael D Hughes, Mary F Kearney, John M Coffin, John W Mellors
• Journal: JCI insight (JCI Insight) Vol. 4 Issue 19 (10 03 2019) ISSN: 2379-3708 [Electronic] United States
• PMID: 31487271 (Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Nevirapine
• Tenofovir
• Emtricitabine

Topics

• Anti-HIV Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Drug Resistance, Viral (drug effects, genetics)
• Emtricitabine (administration & dosage, therapeutic use)
• Female
• Genome, Viral
• HIV Infections (drug therapy)
• HIV-1 (drug effects, genetics)
• Humans
• Mutation
• Nevirapine (administration & dosage, therapeutic use)
• Tenofovir (administration & dosage, therapeutic use)
• Treatment Failure
• Whole Genome Sequencing